Kenvue Inc. (NYSE:KVUE) Shares Acquired by M&T Bank Corp

M&T Bank Corp increased its holdings in Kenvue Inc. (NYSE:KVUE) by 4.6% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 106,594 shares of the company’s stock after purchasing an additional 4,654 shares during the quarter. M&T Bank Corp’s holdings in Kenvue were worth $2,465,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in KVUE. Riverview Trust Co purchased a new stake in shares of Kenvue in the third quarter valued at about $30,000. Ashton Thomas Securities LLC acquired a new stake in Kenvue during the 3rd quarter valued at $35,000. Deseret Mutual Benefit Administrators grew its holdings in Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after buying an additional 651 shares during the last quarter. Studio Investment Management LLC increased its position in Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after buying an additional 845 shares in the last quarter. Finally, Brooklyn Investment Group acquired a new position in shares of Kenvue in the third quarter worth $71,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Down 0.5 %

Shares of KVUE stock opened at $22.21 on Friday. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The firm’s 50 day moving average price is $22.95 and its two-hundred day moving average price is $21.17. The stock has a market cap of $42.58 billion, a price-to-earnings ratio of 40.38, a price-to-earnings-growth ratio of 2.02 and a beta of 1.36. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the prior year, the company earned $0.31 EPS. The firm’s revenue was down .4% on a year-over-year basis. On average, analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.69%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analysts Set New Price Targets

A number of analysts recently commented on KVUE shares. Bank of America lifted their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Piper Sandler boosted their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Jefferies Financial Group started coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price for the company. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the stock from $25.00 to $24.00 in a research note on Thursday. Finally, JPMorgan Chase & Co. lifted their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.